These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 28480310)

  • 21. Gene transfer into hematopoietic stem cells using lentiviral vectors.
    Scherr M; Eder M
    Curr Gene Ther; 2002 Feb; 2(1):45-55. PubMed ID: 12108973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
    Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T
    J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term expression of human adenosine deaminase in mice transplanted with retrovirus-infected hematopoietic stem cells.
    Lim B; Apperley JF; Orkin SH; Williams DA
    Proc Natl Acad Sci U S A; 1989 Nov; 86(22):8892-6. PubMed ID: 2573068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies.
    Silver JN; Flotte TR
    Pharmacogenomics; 2008 Jul; 9(7):947-68. PubMed ID: 18597656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Gene therapy for adenosine deaminase (ADA) deficiency: review of the past, the present and the future].
    Ariga T
    Nihon Rinsho; 2001 Jan; 59(1):72-5. PubMed ID: 11197865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on gene therapy for hereditary hematological disorders.
    Herzog RW; Arruda VR
    Expert Rev Cardiovasc Ther; 2003 Jul; 1(2):215-32. PubMed ID: 15030282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone marrow gene therapy for adenosine deaminase deficiency.
    Kaptein LC; Einerhand MP; Braakman E; Valerio D; van Beusechem VW
    Immunodeficiency; 1993; 4(1-4):335-45. PubMed ID: 7909479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene transfer of adenosine deaminase into primitive human hematopoietic progenitor cells.
    Cournoyer D; Scarpa M; Mitani K; Moore KA; Markowitz D; Bank A; Belmont JW; Caskey CT
    Hum Gene Ther; 1991; 2(3):203-13. PubMed ID: 1751590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone marrow transplantation and alternatives for adenosine deaminase deficiency.
    Gaspar HB
    Immunol Allergy Clin North Am; 2010 May; 30(2):221-36. PubMed ID: 20493398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene therapy for genetic haematological disorders and immunodeficiencies.
    Kohn DB
    J Intern Med; 2001 Apr; 249(4):379-90. PubMed ID: 11298858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A possible turning point in the hematopoietic stem cell gene therapy for primary immunodeficiency diseases? Lentiviral vectors could take the place of retroviral vectors.
    Ariga T
    Expert Rev Clin Immunol; 2013 Nov; 9(11):1015-8. PubMed ID: 24168409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of Different Cytokine Conditions Reveals Resveratrol as a New Molecule for Ex Vivo Cultivation of Cord Blood-Derived Hematopoietic Stem Cells.
    Heinz N; Ehrnström B; Schambach A; Schwarzer A; Modlich U; Schiedlmeier B
    Stem Cells Transl Med; 2015 Sep; 4(9):1064-72. PubMed ID: 26160960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective TREC testing of newborns with Severe Combined Immunodeficiency and other primary immunodeficiency diseases.
    Jilkina O; Thompson JR; Kwan L; Van Caeseele P; Rockman-Greenberg C; Schroeder ML
    Mol Genet Metab Rep; 2014; 1():324-333. PubMed ID: 27896105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug evaluation: ADA-transduced hematopoietic stem cell therapy for ADA-SCID.
    Taupin P
    IDrugs; 2006 Jun; 9(6):423-30. PubMed ID: 16752313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID.
    Bordignon C; Mavilio F; Ferrari G; Servida P; Ugazio AG; Notarangelo LD; Gilboa E; Rossini S; O'Reilly RJ; Smith CA
    Hum Gene Ther; 1993 Aug; 4(4):513-20. PubMed ID: 8399494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene therapy of severe combined immunodeficiencies.
    Cavazzana-Calvo M; Hacein-Bey S; Yates F; de Villartay JP; Le Deist F; Fischer A
    J Gene Med; 2001; 3(3):201-6. PubMed ID: 11437325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical gene therapy in hematology: past and future.
    Richter J; Karlsson S
    Int J Hematol; 2001 Feb; 73(2):162-9. PubMed ID: 11372727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene therapy for ADA-SCID, the first marketing approval of an
    Aiuti A; Roncarolo MG; Naldini L
    EMBO Mol Med; 2017 Jun; 9(6):737-740. PubMed ID: 28396566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene therapy for adenosine deaminase deficiency.
    Aiuti A; Ficara F; Cattaneo F; Bordignon C; Roncarolo MG
    Curr Opin Allergy Clin Immunol; 2003 Dec; 3(6):461-6. PubMed ID: 14612670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone marrow gene transfer in three patients with adenosine deaminase deficiency.
    Hoogerbrugge PM; van Beusechem VW; Fischer A; Debree M; le Deist F; Perignon JL; Morgan G; Gaspar B; Fairbanks LD; Skeoch CH; Moseley A; Harvey M; Levinsky RJ; Valerio D
    Gene Ther; 1996 Feb; 3(2):179-83. PubMed ID: 8867866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.